IDP-121 c-Myc inhibitor spun-out into a new company for clinical development

Business, important, news

IDP-121, a c-Myc specific inhibitor with broad applications in cancer, will continue its clinical development in TheraMyc Inc., a new company stablished to boost its clinical development.

IDP-121 was developed thanks to IDP Platform, a unique technology that allows to design for the first time drugs targeting intrinsically disordered transcription factors.